Envista Holdings Co. (NYSE:NVST) Receives $20.13 Average Price Target from Analysts

Shares of Envista Holdings Co. (NYSE:NVST) have been assigned an average recommendation of “Hold” from the fifteen analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $20.13.

NVST has been the subject of several recent analyst reports. Wells Fargo & Company assumed coverage on shares of Envista in a research report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 target price for the company. Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Stifel Nicolaus upped their price target on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Robert W. Baird upped their price target on shares of Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group upped their price target on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd.

Envista Price Performance

NYSE NVST opened at $21.42 on Friday. Envista has a 52 week low of $15.15 and a 52 week high of $24.79. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The stock has a market cap of $3.69 billion, a price-to-earnings ratio of -2.76, a price-to-earnings-growth ratio of 1.88 and a beta of 1.33. The company has a 50-day moving average price of $20.10 and a two-hundred day moving average price of $18.96.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The firm had revenue of $601.00 million during the quarter, compared to analysts’ expectations of $590.34 million. During the same quarter in the prior year, the firm earned $0.43 EPS. Envista’s quarterly revenue was down 4.8% on a year-over-year basis. Analysts forecast that Envista will post 0.72 EPS for the current year.

Institutional Investors Weigh In On Envista

Several hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares in the last quarter. Huntington National Bank lifted its position in shares of Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after acquiring an additional 949 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in shares of Envista by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 19,887 shares of the company’s stock valued at $392,000 after acquiring an additional 1,355 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.